Carbylan Therapeutics Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$30.6M
- Investors
-
2
Carbylan Therapeutics General Information
Description
Operator of a clinical-stage specialty pharmaceutical company intended to treat pain associated with osteoarthritis of the knee. The company is focused on the development and commercialization of proprietary combination therapies such as polysaccharides, biopolymers and other related pharmaceutical products.
Contact Information
Website
www.carbylan.comCorporate Office
- 3181 Porter Drive
- Palo Alto, CA 94304
- United States
Corporate Office
- 3181 Porter Drive
- Palo Alto, CA 94304
- United States
Carbylan Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 21-Nov-2016 | $30.6M | Completed | Generating Revenue | ||
| 7. Grant | 01-Jun-2015 | Completed | Generating Revenue | |||
| 6. IPO | 08-Apr-2015 | Completed | Generating Revenue | |||
| 5. Debt - General | 09-Mar-2015 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 14-Oct-2014 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 03-Jan-2013 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 13-Jan-2006 | $7.91M | $7.91M | Completed | Product Development | |
| 1. University Spin-Out | 01-Jan-2004 | Completed | Startup |
Carbylan Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Carbylan Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Carbylan Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| InterWest Partners | Venture Capital | Minority | ||
| Vivo Capital | Venture Capital | Minority |
Carbylan Therapeutics Acquisitions (1)
Carbylan Therapeutics’s most recent deal was a Reverse Merger with KalVista Pharmaceuticals. The deal was made on 22-Nov-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| KalVista Pharmaceuticals | 22-Nov-2016 | Reverse Merger | Drug Discovery |
Carbylan Therapeutics FAQs
-
When was Carbylan Therapeutics founded?
Carbylan Therapeutics was founded in 2004.
-
Where is Carbylan Therapeutics headquartered?
Carbylan Therapeutics is headquartered in Palo Alto, CA.
-
What industry is Carbylan Therapeutics in?
Carbylan Therapeutics’s primary industry is Drug Discovery.
-
Is Carbylan Therapeutics a private or public company?
Carbylan Therapeutics is a Private company.
-
What is the current valuation of Carbylan Therapeutics?
The current valuation of Carbylan Therapeutics is .
-
What is Carbylan Therapeutics’s current revenue?
The current revenue for Carbylan Therapeutics is .
-
How much funding has Carbylan Therapeutics raised over time?
Carbylan Therapeutics has raised $103M.
-
Who are Carbylan Therapeutics’s investors?
Alta Partners, InterWest Partners, and Vivo Capital have invested in Carbylan Therapeutics.
-
When was Carbylan Therapeutics acquired?
Carbylan Therapeutics was acquired on 21-Nov-2016.
-
Who acquired Carbylan Therapeutics?
Carbylan Therapeutics was acquired by KalVista Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
